Nothing Special   »   [go: up one dir, main page]

MX2022015026A - Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. - Google Patents

Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.

Info

Publication number
MX2022015026A
MX2022015026A MX2022015026A MX2022015026A MX2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A
Authority
MX
Mexico
Prior art keywords
membered heteroaromatic
imidazole compound
compound
imidazole
medicament
Prior art date
Application number
MX2022015026A
Other languages
English (en)
Inventor
Shuhui Chen
Chengde Wu
Tao Yu
Lu Gan
Original Assignee
Hangzhou Sciwind Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Sciwind Biosciences Co Ltd filed Critical Hangzhou Sciwind Biosciences Co Ltd
Publication of MX2022015026A publication Critical patent/MX2022015026A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un compuesto de imidazol heteroaromático de cinco miembros novedoso y su uso en la preparación de un medicamento para el tratamiento de enfermedades relacionadas. Específicamente, se divulga un compuesto como se muestra en la fórmula (III) y una sal farmacéuticamente aceptable del mismo. (ver Fórmula).
MX2022015026A 2020-06-04 2021-06-04 Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. MX2022015026A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010499820 2020-06-04
CN202010676014 2020-07-14
CN202010838768 2020-08-19
PCT/CN2021/098424 WO2021244645A1 (zh) 2020-06-04 2021-06-04 五元杂芳并咪唑类化合物及其应用

Publications (1)

Publication Number Publication Date
MX2022015026A true MX2022015026A (es) 2023-01-04

Family

ID=78830627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015026A MX2022015026A (es) 2020-06-04 2021-06-04 Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.

Country Status (11)

Country Link
US (1) US11542272B2 (es)
EP (1) EP4155313A4 (es)
JP (1) JP7359974B2 (es)
KR (1) KR102588241B1 (es)
CN (1) CN115698022B (es)
AU (1) AU2021286086B2 (es)
CA (1) CA3181120C (es)
IL (1) IL298753B2 (es)
MX (1) MX2022015026A (es)
NZ (1) NZ796075A (es)
WO (1) WO2021244645A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7558267B2 (ja) 2019-10-25 2024-09-30 ギリアード サイエンシーズ， インコーポレイテッド Ｇｌｐ－１ｒ調節化合物
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
CR20230066A (es) 2020-08-06 2023-05-29 Gasherbrum Bio Inc Agonistas del glp-1 heterocíclicos
EP4204415A1 (en) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
MX2023007569A (es) * 2020-12-25 2023-09-21 Xizang Haisco Pharmaceutical Co Ltd Derivado de anillo de cinco miembros y uso medico de este.
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4317145A1 (en) 2021-03-24 2024-02-07 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
WO2022225941A1 (en) 2021-04-21 2022-10-27 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JPWO2023038039A1 (es) 2021-09-08 2023-03-16
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
AU2022358915A1 (en) 2021-10-05 2024-05-09 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2022401795A1 (en) * 2021-12-03 2024-07-04 Hangzhou Sciwind Biosciences Co., Ltd. Crystal forms of thienoimidazole compound and preparation method thereof
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023124824A1 (zh) * 2021-12-29 2023-07-06 海思科医药集团股份有限公司 一种glp-1激动剂的盐及其晶型和在医药上的应用
WO2023125896A1 (zh) * 2021-12-31 2023-07-06 海思科医药集团股份有限公司 一种glp-1激动剂中间体及其制备方法及在医药中的用途
CN118613476A (zh) * 2022-01-10 2024-09-06 西藏海思科制药有限公司 一种glp-1激动剂盐及其晶型及在医药上的应用
KR20240148000A (ko) * 2022-02-28 2024-10-10 애슬레티스 바이오사이언스 코., 엘티디. Glp-1r 조절 화합물
TW202408504A (zh) * 2022-06-23 2024-03-01 大陸商西藏海思科製藥有限公司 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途
TW202412796A (zh) * 2022-06-23 2024-04-01 大陸商西藏海思科製藥有限公司 五並五員環衍生物的藥物組合物及其在醫藥上的應用
WO2024063143A1 (ja) * 2022-09-22 2024-03-28 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166621A1 (en) 2012-05-09 2013-11-14 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
GEP20217265B (en) 2016-12-16 2021-06-25 Pfizer Glp-1 receptor agonists and uses thereof
AU2019285570B2 (en) * 2018-06-15 2022-03-24 Pfizer Inc. GLP-1 receptor agonists and uses thereof
EA202191432A1 (ru) 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
JP2023539584A (ja) * 2020-09-01 2023-09-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
MX2023007569A (es) * 2020-12-25 2023-09-21 Xizang Haisco Pharmaceutical Co Ltd Derivado de anillo de cinco miembros y uso medico de este.

Also Published As

Publication number Publication date
KR102588241B1 (ko) 2023-10-11
KR20230016701A (ko) 2023-02-02
AU2021286086A1 (en) 2023-02-09
AU2021286086B2 (en) 2023-09-07
EP4155313A4 (en) 2023-09-13
CN115698022A (zh) 2023-02-03
CN115698022B (zh) 2024-03-15
IL298753B2 (en) 2024-05-01
IL298753A (en) 2023-02-01
NZ796075A (en) 2023-04-28
US11542272B2 (en) 2023-01-03
JP2023520260A (ja) 2023-05-16
BR112022023879A2 (pt) 2022-12-27
EP4155313A1 (en) 2023-03-29
JP7359974B2 (ja) 2023-10-11
WO2021244645A1 (zh) 2021-12-09
US20220135588A1 (en) 2022-05-05
CA3181120C (en) 2024-01-02
CA3181120A1 (en) 2021-12-09
IL298753B1 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
NZ796075A (en) Five-membered heteroaromatic imidazole compound and use thereof
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
MX2020010407A (es) Benzotiofenos y compuestos relacionados como agonistas de sting.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EP4331677A3 (en) Methods of treating feline coronavirus infections
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
CA3082011A1 (en) Methods of using substituted pyrazole and pyrrole compounds and for treatment of hyperproliferative diseases
MX2024001924A (es) Benzo derivado de anillo heteroaromatico que contiene nitrogeno y uso del mismo en medicina.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2021012105A (es) Compuestos de pirrol.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX2024001352A (es) Inhibidor novedoso de la poli(adp-ribosa) polimerasa y uso del mismo.
PH12019550154A1 (en) Azetidine derivative
MX2021007140A (es) Compuesto para usarse en enfermedades de la retina.
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2022003270A (es) Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
MX2023007579A (es) Derivado de borato y usos del mismo.
MX2023000382A (es) Inmunomoduladores heterocíclicos.
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
MX345264B (es) Derivado de azol.
MX2024004871A (es) Compuesto que contiene piridilo.
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor